皮肤生物学的分子革命:基因组皮肤病学的新机制、基因编辑与治疗突破
基因组学技术进步推动了对皮肤病缺陷、生物学通路及治疗靶点的理解,下一代测序革新了致病基因鉴定。基因添加策略在交界性大疱性表皮松解症和隐性营养不良性大疱性表皮松解症中显示疗效,TALENs和CRISPR/Cas9成为高效基因组编辑工具。对皮肤病发病机制的深入理解促进了特异性药物开发或现有药物重定位,为罕见和常见皮肤病的靶向个性化医疗铺路。
要点
- 下一代测序革新了皮肤病致病基因鉴定与基因/蛋白特征解析。
- 基因添加策略在交界性和隐性营养不良性大疱性表皮松解症中显示疗效。
- TALENs和CRISPR/Cas9可创建新模型并纠正或破坏突变基因以治疗人类疾病。
核心结论
- 基因组学技术进步为罕见和常见皮肤病开发靶向个性化医疗开辟了道路。
研究设计与样本
- 本文为综述,总结基因组学在皮肤生物学中的分子进展,未报告具体样本量。
主要发现
- 下一代测序革新了致病基因鉴定,对解析罕见和常见皮肤病的基因与蛋白特征有深远影响。
- 基因添加策略在交界性大疱性表皮松解症和隐性营养不良性大疱性表皮松解症中显示疗效。
- TALENs和CRISPR/Cas9成为高效编辑基因组序列的新工具,可创建新模型并纠正或破坏突变基因。
- 治疗策略不限于DNA修饰,mRNA、蛋白和细胞水平策略也已出现,部分在隐性营养不良性大疱性表皮松解症中已证实临床疗效。
- 对皮肤病发病机制的理解改善促进了特异性药物开发或现有药物重定位,如基底细胞痣综合征、斑秃、黑色素瘤和大疱性表皮松解症。
临床怎么用
- 基因编辑工具可用于创建皮肤病模型并纠正或破坏突变基因以治疗人类疾病。
- 基因添加策略可用于交界性和隐性营养不良性大疱性表皮松解症的治疗。
- 基于发病机制理解的特异性药物或药物重定位可用于基底细胞痣综合征、斑秃、黑色素瘤和大疱性表皮松解症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stunning technological advances in genomics have led to spectacular breakthroughs in the understanding of the underlying defects, biological pathways and therapeutic targets of skin diseases leading to new therapeutic interventions. Next-generation sequencing has revolutionized the identification of disease-causing genes and has a profound impact in deciphering gene and protein signatures in rare and frequent skin diseases. Gene addition strategies have shown efficacy in junctional EB and in recessive dystrophic EB (RDEB). TALENs and Cripsr/Cas9 have emerged as highly efficient new tools to edit genomic sequences to creat new models and to correct or disrupt mutated genes to treat human diseases. Therapeutic approaches have not been limited to DNA modification and strategies at the mRNA, protein and cellular levels have also emerged, some of which have already proven clinical efficacy in RDEB. Improved understanding of the pathogenesis of skin disorders has led to the development of specific drugs or repurposing of existing medicines as in basal cell nevus syndrome, alopecia areata, melanoma and EB simplex. These discoveries pave the way for improved targeted personalized medicine for rare and frequent diseases. It is likely that a growing number of orphan skin diseases will benefit from combinatory new therapies in a near future.
引用
- Titeux M, Izmiryan A, Hovnanian A, et al. The Molecular Revolution in Cutaneous Biology: Emerging Landscape in Genomic Dermatology: New Mechanistic Ideas, Gene Editing, and Therapeutic Breakthroughs. J Invest Dermatol. 2017. PMID: 28411843. doi:10.1016/j.jid.2016.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。